{
    "clinical_study": {
        "@rank": "36809", 
        "arm_group": [
            {
                "arm_group_label": "Programmed Intermittent Epidural Bolus", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Continuous Epidural Infusion", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study included women who underwent voluntary second trimester termination of pregnancy.\n      Patients were randomized to programmed intermittent epidural anesthetic bolus or continuous\n      epidural infusion for pain analgesia. In this randomized, double-blind study, the\n      investigators assess the incidence of motor block (primary outcome), degree of satisfaction\n      of the patients, total levobupivacaine and sufentanil consumption and adverse events\n      (secondary outcomes) between the two study groups."
        }, 
        "brief_title": "Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Termination of Pregnancy Analgesia", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "B1", 
                            "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nContinuous Epidural Infusion : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                            "title": "Continuous Epidural Infusion"
                        }, 
                        {
                            "@group_id": "B2", 
                            "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nProgrammed Intermittent Epidural Bolus : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                            "title": "Programmed Intermittent Epidural Bolus"
                        }, 
                        {
                            "@group_id": "B3", 
                            "description": "Total of all reporting groups", 
                            "title": "Total"
                        }
                    ]
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "52"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "52"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "104"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "0"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "52"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "52"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "104"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "0"
                                                }
                                            ]
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@spread": "4.7", 
                                                "@value": "33.3"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@spread": "5.3", 
                                                "@value": "32.4"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@spread": "5.0", 
                                                "@value": "32.8"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "52"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "52"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "104"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "0"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "52"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "52"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "104"
                                            }
                                        ]
                                    }, 
                                    "sub_title": "Italy"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "analysis_list": {
                            "analysis": {
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "method": "Chi-squared", 
                                "non_inferiority": "No", 
                                "p_value": "< 0.001"
                            }
                        }, 
                        "description": "The assessment of the degree of motor block was performed in the right and left lower extremities using the Breen modified Bromage score: 1 = complete block (unable to move feet or knees), 2 = almost complete block (able to move feet only), 3 = partial block (just able to move knees), 4 = detectable weakness of hip flexion while supine (between scores 3 and 5), 5 = no detectable weakness of hip flexion while supine (full flexion of knees), and 6 = able to stand and to perform partial knee bend. Patients with a Bromage score < 6 were considered to have motor block.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nContinuous Epidural Infusion : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                                    "title": "Continuous Epidural Infusion"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nProgrammed Intermittent Epidural Bolus : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                                    "title": "Programmed Intermittent Epidural Bolus"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "52"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "52"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "24"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "3"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "The assessment of the degree of motor block was performed in the right and left lower extremities using the Breen modified Bromage score: 1 = complete block (unable to move feet or knees), 2 = almost complete block (able to move feet only), 3 = partial block (just able to move knees), 4 = detectable weakness of hip flexion while supine (between scores 3 and 5), 5 = no detectable weakness of hip flexion while supine (full flexion of knees), and 6 = able to stand and to perform partial knee bend. Patients with a Bromage score < 6 were considered to have motor block.", 
                                    "param": "Number", 
                                    "title": "Incidence of Motor Block", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "safety_issue": "No", 
                        "time_frame": "Assessed every hour from starting the analgesia procedure (up to 66 hours from starting of the procedure).", 
                        "title": "Incidence of Motor Block", 
                        "type": "Primary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "method": "Wilcoxon (Mann-Whitney)", 
                                "non_inferiority": "No", 
                                "p_value": "0.005"
                            }
                        }, 
                        "description": "At discharge from the hospital, patients were requested to answer the following question \u201cTaking into consideration the variations in pain symptoms, as well as the adverse events experienced, if any, how would you define the grade of satisfaction with your analgesic treatment?\u201d The grade of satisfaction was assessed using a visual analog scale (VAS) where 0 corresponded to \u201ccompletely unsatisfied\u201d and 100 to \u201ccompletely satisfied\u201d.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nContinuous Epidural Infusion : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                                    "title": "Continuous Epidural Infusion"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nProgrammed Intermittent Epidural Bolus : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                                    "title": "Programmed Intermittent Epidural Bolus"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "52"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "52"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "19.6", 
                                                        "@value": "73.2"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "15.2", 
                                                        "@value": "84.4"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "At discharge from the hospital, patients were requested to answer the following question \u201cTaking into consideration the variations in pain symptoms, as well as the adverse events experienced, if any, how would you define the grade of satisfaction with your analgesic treatment?\u201d The grade of satisfaction was assessed using a visual analog scale (VAS) where 0 corresponded to \u201ccompletely unsatisfied\u201d and 100 to \u201ccompletely satisfied\u201d.", 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Degree of Satisfaction of the Patients With the Analgesia Procedure", 
                                    "units": "mm"
                                }
                            ]
                        }, 
                        "safety_issue": "No", 
                        "time_frame": "At discharge from the hospital (up to 72 hours from starting of the procedure).", 
                        "title": "Degree of Satisfaction of the Patients With the Analgesia Procedure", 
                        "type": "Secondary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "method": "Wilcoxon (Mann-Whitney)", 
                                "non_inferiority": "No", 
                                "p_value": "0.047"
                            }
                        }, 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nContinuous Epidural Infusion : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                                    "title": "Continuous Epidural Infusion"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nProgrammed Intermittent Epidural Bolus : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                                    "title": "Programmed Intermittent Epidural Bolus"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "52"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "52"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "27.0", 
                                                        "@value": "86.2"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "26.8", 
                                                        "@value": "75.5"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Total Levobupivacaine Consumption", 
                                    "units": "mg"
                                }
                            ]
                        }, 
                        "safety_issue": "No", 
                        "time_frame": "At the moment of fetal expulsion (up to 66 hours from starting of the procedure).", 
                        "title": "Total Levobupivacaine Consumption", 
                        "type": "Secondary"
                    }, 
                    {
                        "analysis_list": {
                            "analysis": {
                                "group_id_list": {
                                    "group_id": [
                                        "O1", 
                                        "O2"
                                    ]
                                }, 
                                "method": "Wilcoxon (Mann-Whitney)", 
                                "non_inferiority": "No", 
                                "p_value": "0.047"
                            }
                        }, 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nContinuous Epidural Infusion : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                                    "title": "Continuous Epidural Infusion"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nProgrammed Intermittent Epidural Bolus : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                                    "title": "Programmed Intermittent Epidural Bolus"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "52"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "52"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@spread": "21.6", 
                                                        "@value": "69.0"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@spread": "21.5", 
                                                        "@value": "60.4"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "dispersion": "Standard Deviation", 
                                    "param": "Mean", 
                                    "title": "Total Sufentanil Consumption.", 
                                    "units": "microg"
                                }
                            ]
                        }, 
                        "safety_issue": "No", 
                        "time_frame": "During the whole analgesia procedure (assessed between the starting of the procedure until 66 hours).", 
                        "title": "Total Sufentanil Consumption.", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "P1", 
                            "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nContinuous Epidural Infusion : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                            "title": "Continuous Epidural Infusion"
                        }, 
                        {
                            "@group_id": "P2", 
                            "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nProgrammed Intermittent Epidural Bolus : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                            "title": "Programmed Intermittent Epidural Bolus"
                        }
                    ]
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "#text": "September 2011", 
                                                "@count": "52", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "#text": "September 2011", 
                                                "@count": "52", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "#text": "June 2013", 
                                                "@count": "52", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "#text": "June 2013", 
                                                "@count": "52", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "recruitment_details": "September 2011 - June 2013. University Hospital."
            }, 
            "point_of_contact": {
                "email": "ulrm@libero.it", 
                "name_or_title": "Dr. Umberto Leone Roberti Maggiore", 
                "organization": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy", 
                "phone": "00393289461340"
            }, 
            "reported_events": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "E1", 
                            "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nContinuous Epidural Infusion : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                            "title": "Continuous Epidural Infusion"
                        }, 
                        {
                            "@group_id": "E2", 
                            "description": "Pump : Pump administering either programmed intermittent epidural bolus or continuous epidural infusion for the maintenance of analgesia was used.\nProgrammed Intermittent Epidural Bolus : An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                            "title": "Programmed Intermittent Epidural Bolus"
                        }
                    ]
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "33", 
                                                "@subjects_at_risk": "52"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "21", 
                                                "@subjects_at_risk": "52"
                                            }
                                        ], 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "18", 
                                                    "@subjects_at_risk": "52"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "7", 
                                                    "@subjects_at_risk": "52"
                                                }
                                            ], 
                                            "sub_title": "Nausea"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "3", 
                                                    "@subjects_at_risk": "52"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "52"
                                                }
                                            ], 
                                            "sub_title": "Vomiting"
                                        }
                                    ]
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "52"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "4", 
                                                    "@subjects_at_risk": "52"
                                                }
                                            ], 
                                            "sub_title": "Hypotension"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "14", 
                                                    "@subjects_at_risk": "52"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "17", 
                                                    "@subjects_at_risk": "52"
                                                }
                                            ], 
                                            "sub_title": "Pruritus"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "11", 
                                                    "@subjects_at_risk": "52"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "9", 
                                                    "@subjects_at_risk": "52"
                                                }
                                            ], 
                                            "sub_title": "Shivering"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "3", 
                                                    "@subjects_at_risk": "52"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "52"
                                                }
                                            ], 
                                            "sub_title": "Sedation"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "52"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "52"
                                                }
                                            ], 
                                            "sub_title": "Respiratory depression"
                                        }
                                    ]
                                }, 
                                "title": "General disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "52"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "52"
                                            }
                                        ], 
                                        "sub_title": "Failure of induction"
                                    }
                                }, 
                                "title": "Pregnancy, puerperium and perinatal conditions"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "frequency_threshold": "1.9"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "52"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "52"
                                            }
                                        ], 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "52"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "3", 
                                                    "@subjects_at_risk": "52"
                                                }
                                            ], 
                                            "sub_title": "Hemorrhage"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "35"
                                                }, 
                                                {
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "37"
                                                }
                                            ], 
                                            "sub_title": "Uterine perforation"
                                        }
                                    ]
                                }, 
                                "title": "Pregnancy, puerperium and perinatal conditions"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment"
                }
            }
        }, 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "condition": "Medical; Abortion, Fetus", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  age \u2265 18 years\n\n          -  pregnancy at second trimester\n\n          -  willingness of voluntary interrupt the pregnancy\n\n          -  comprehension of Italian Language\n\n          -  baseline pain score \u2265 30 on a 100-mm visual analog pain scale (VAPS)\n\n        Exclusion Criteria:\n\n          -  contraindication to epidural analgesia and  to narcotics\n\n          -  history of drug abuse or chronic use\n\n          -  maternal disease (such as severe asthma, cardiac, liver or kidney disease)\n\n          -  inability to comprehend or comply with the analgesia pain management procedures."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "104", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 13, 2013", 
        "firstreceived_results_date": "June 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01860521", 
            "org_study_id": "SCUL 4022"
        }, 
        "intervention": [
            {
                "arm_group_label": "Programmed Intermittent Epidural Bolus", 
                "description": "An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                "intervention_name": "Programmed Intermittent Epidural Bolus", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Continuous Epidural Infusion", 
                "description": "An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine\u00ae, Abbott, Chicago, USA) plus sufentanil 10 \u00b5g (Fentatienil\u00ae, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 \u00b5g/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score \u2265 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.", 
                "intervention_name": "Continuous Epidural Infusion", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Programmed Intermittent Epidural Bolus", 
                    "Continuous Epidural Infusion"
                ], 
                "description": "Patients were administered 1 mg of gemeprost pessaries (Cervidil\u00ae, Merck Serono SPA, Roma, Italy) in the posterior fornix of the vagina every 3 hours up to 5 doses. If the expulsion of the fetus did not occur, the therapeutic regimen was repeated after 24 hours from the initiation of the treatment. Induction-to-abortion time (hours) was considered the period of time comprised between the first gemeprost pessary administration and fetal expulsion. Failure of induction of abortion was defined as women undelivered after two completed cycles (48h).The evacuation of the uterus under general anesthesia was performed if ultrasonography showed retained productions of conception.", 
                "intervention_name": "Procedure of interruption of pregnancy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Programmed Intermittent Epidural Bolus", 
                    "Continuous Epidural Infusion"
                ], 
                "description": "Levobupivacaine (Chirocaine\u00ae, Abbott, Chicago, IL, USA) and sufentanil(Fentatienil\u00ae, Angelini, Rome, Italy) were administered in both study groups according to the regimen of each intervention arm (Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion).", 
                "intervention_name": "Drug used for analgesia procedures", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Levobupivacaine: Chirocaine\u00ae, Abbott, Chicago, IL, USA.", 
                    "Sufentanil: Fentatienil\u00ae, Angelini, Rome, Italy."
                ]
            }, 
            {
                "arm_group_label": "Programmed Intermittent Epidural Bolus", 
                "description": "Pump administering programmed intermittent epidural bolus for the maintenance of analgesia was used.", 
                "intervention_name": "Pump for programmed intermittent bolus.", 
                "intervention_type": "Device", 
                "other_name": "Pump: Gemstar\u00ae; Hospira, Lake Forest, USA."
            }, 
            {
                "arm_group_label": "Continuous Epidural Infusion", 
                "description": "Pump administering continuous epidural infusion for the maintenance of analgesia was used.", 
                "intervention_name": "Pump for continuous epidural infusion.", 
                "intervention_type": "Device", 
                "other_name": "Pump: Gemstar\u00ae; Hospira, Lake Forest, USA."
            }, 
            {
                "arm_group_label": [
                    "Programmed Intermittent Epidural Bolus", 
                    "Continuous Epidural Infusion"
                ], 
                "description": "Gemeprost pessaries.", 
                "intervention_name": "Drug used for termination of pregnancy procedure.", 
                "intervention_type": "Drug", 
                "other_name": "Gemeprost pessaries: Cervidil\u00ae, Merck Serono SPA, Rome, Italy."
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemeprost", 
                "Sufentanil", 
                "Levobupivacaine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Termination of pregnancy", 
            "Second trimester", 
            "Programmed intermittent epidural bolus", 
            "Continuous epidural infusion", 
            "Epidural analgesia", 
            "Legally Induced Abortion"
        ], 
        "lastchanged_date": "August 19, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Genoa", 
                    "country": "Italy", 
                    "state": "Ligury", 
                    "zip": "16132"
                }, 
                "name": "Department of Obstetrics and Gynecology, San Martino Hospital and National Institute for Cancer Research, University of Genoa"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "2", 
        "official_title": "Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion for Second Trimester Voluntary Termination of Pregnancy Analgesia: a Randomized Study.", 
        "overall_official": [
            {
                "affiliation": "University of Genoa", 
                "last_name": "Simone Ferrero, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University of Genoa", 
                "last_name": "Umberto Leone Roberti Maggiore, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Italy: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The assessment of the degree of motor block was performed in the right and left lower extremities using the Breen modified Bromage score: 1 = complete block (unable to move feet or knees), 2 = almost complete block (able to move feet only), 3 = partial block (just able to move knees), 4 = detectable weakness of hip flexion while supine (between scores 3 and 5), 5 = no detectable weakness of hip flexion while supine (full flexion of knees), and 6 = able to stand and to perform partial knee bend. Patients with a Bromage score < 6 were considered to have motor block.", 
            "measure": "Incidence of Motor Block", 
            "safety_issue": "No", 
            "time_frame": "Assessed every hour from starting the analgesia procedure (up to 66 hours from starting of the procedure)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01860521"
        }, 
        "responsible_party": {
            "investigator_affiliation": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy", 
            "investigator_full_name": "Umberto Leone Roberti Maggiore", 
            "investigator_title": "Principal Investigator, Research Fellow.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "At discharge from the hospital, patients were requested to answer the following question \"Taking into consideration the variations in pain symptoms, as well as the adverse events experienced, if any, how would you define the grade of satisfaction with your analgesic treatment?\" The grade of satisfaction was assessed using a visual analog scale (VAS) where 0 corresponded to \"completely unsatisfied\" and 100 to \"completely satisfied\".", 
                "measure": "Degree of Satisfaction of the Patients With the Analgesia Procedure", 
                "safety_issue": "No", 
                "time_frame": "At discharge from the hospital (up to 72 hours from starting of the procedure)."
            }, 
            {
                "measure": "Total Levobupivacaine Consumption", 
                "safety_issue": "No", 
                "time_frame": "At the moment of fetal expulsion (up to 66 hours from starting of the procedure)."
            }, 
            {
                "measure": "Total Sufentanil Consumption.", 
                "safety_issue": "No", 
                "time_frame": "During the whole analgesia procedure (assessed between the starting of the procedure until 66 hours)."
            }
        ], 
        "source": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}